- The Swiss AmVac AG, a biopharmaceutical company
located in Zug, has made significant advances in the manufacture and
production of its vaccine candidate against RSV over the last few
months. This vaccine candidate is based on the new Sendai vector
technology for which Max-Planck-Innovations GmbH has acquired the
exclusive licence. This technology, which has been developed by Prof.
Wolfgang Neubert's group at the Max Planck Institute of Biochemistry,
can be used for many indications. The initial aim is to offer
protection against the respiratory syncytial virus (RSV) with a
vaccine produced on this basis. RSV is a viral pathogen that causes
severe airway diseases that are characterised by loss of function of
the mucous membranes. This leads to reduced oxygen uptake and very
distressing breathlessness. Young children, the elderly, and
individuals with a weakened immune system are particularly affected
by this flu-like viral disease. Following the successful technology
transfer from the Max-Planck-Institute with tremendous support from
Prof. Wolfgang Neubert, and setting up and training the AmVac
Research GmbH team, major advances have already been made in the
manufacture and production of the RSC vaccine candidate. Therefore,
AmVac Research GmbH is confident that the proof of principle results
from animal models will already become available this year. This
would be a major step forward towards the intended aim of using the
vaccine for humans.
Sendai vector platform technology is an innovative vaccine
platform for the development of a novel generation of live vaccines.
It has been developed at the Max Planck Institute of Biochemistry in
Munich under the leadership of Prof. Dr Wolfgang Neubert.
Furthermore, AmVac AG is also in possession of the adjuvant family
Malp 2, licensed from the Helmholtz-Institute in Hanover. Both
technologies are now to be advanced and optimised together with the
scientific developers of the two technologies, Prof. Dr Wolfgang
Neubert and Prof. Dr Carlos Guzman, with the support of Prof. Dr
Reinhard Glück, President of the Advisory Board and the Swiss Biotech
Association. This concentration of the platform technologies allows
for significant costs savings in scientific staffing levels.
AmVac AG is a biopharmaceutical company situated in Switzerland.
The company focuses on the vaccine market with its above-average
growth figures. There are two therapeutic vaccines in the pipeline,
which are soon to be launched in the fields of gynaecology and
urology. Further innovative vaccines and technologies are at the
development stage. The renowned market research company Frost &
Sullivan awarded AmVac AG the coveted prize "Enabling Technology of
the Year Award" in 2007.
ots Originaltext: AmVac AG
Ariane Meynert, Head of PR/IR